Risankizumab
- Generic Name
- Risankizumab
- Brand Names
- Skyrizi 150 Mg Dose Pack, Skyrizi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1612838-76-2
- Unique Ingredient Identifier
- 90ZX3Q3FR7
- Background
Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. Risankizumab is being investigated for...
- Indication
Risankizumab is indicated to treat:
- Associated Conditions
- Moderate plaque-type psoriasis, Psoriasis, Psoriatic Arthritis, Severe Plaque Type Psoriasis, Active Psoriatic arthritis, Moderate, active Crohn´s Disease, Moderate, severe Psoriasis Vulgaris (Plaque Psoriasis), Severe, active Crohn´s Disease
- Associated Therapies
- -
Evaluation of Sonelokimab in Patients with Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
- Conditions
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 600
- Registration Number
- NCT06641089
- Locations
- 🇺🇸
Clinical Site, Lubbock, Texas, United States
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 550
- Registration Number
- NCT06624228
- Locations
- 🇨🇿
Pa0016 40010, Uherske Hradiste, Czechia
🇩🇪Pa0016 40800, Ratingen, Germany
🇭🇺Pa0016 40081, Budapest, Hungary
A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 231
- Registration Number
- NCT06571266
- Locations
- 🇺🇸
Cenexel Act /ID# 270310, Anaheim, California, United States
🇺🇸Collaborative Neuroscience Research CNS /ID# 270286, Los Alamitos, California, United States
🇺🇸Acpru /Id# 270152, Grayslake, Illinois, United States
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 500
- Registration Number
- NCT06548542
- Locations
- 🇵🇹
2CA-Braga, Hospital de Braga /ID# 265894, Braga, Portugal
🇵🇹Unidade Local de Saude de Coimbra, EPE /ID# 267240, Coimbra, Portugal
🇵🇹Unidade Local de Saude de Lisboa Ocidental, EPE /ID# 267242, Lisboa, Portugal
A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT06487572
- Locations
- 🇺🇸
Clinical Pharmacology Of Miami /ID# 268219, Miami, Florida, United States
🇺🇸Acpru /Id# 267057, Grayslake, Illinois, United States
A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease
- Conditions
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 10
- Registration Number
- NCT06346288
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill /ID# 263316, Chapel Hill, North Carolina, United States
🇮🇱Shaare Zedek Medical Center /ID# 262738, Jerusalem, Yerushalayim, Israel
🇺🇸UTHealth Women's Research Program - Memorial City /ID# 263939, Houston, Texas, United States
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 336
- Registration Number
- NCT06333860
- Locations
- 🇨🇦
Private Practice - Dr. Angelique Gagne-Henley /ID# 264267, St-Jérôme, Quebec, Canada
🇩🇪Universitaetsklinikum Freiburg /ID# 263069, Freiburg, Baden-Wuerttemberg, Germany
🇩🇪Beldio Research GmbH /ID# 263073, Memmingen, Bayern, Germany
Risankizumab in Children With Crohn's Disease (RisaKids)
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Shaare Zedek Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT06298188
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
- Conditions
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 40
- Registration Number
- NCT06100744
- Locations
- 🇺🇸
Arkansas Children's Hospital /ID# 258776, Little Rock, Arkansas, United States
🇺🇸Joe Dimaggio Children's Hospital Hollywood /ID# 260634, Hollywood, Florida, United States
🇺🇸Indiana University Health Riley Hospital for Children /ID# 259067, Indianapolis, Indiana, United States
A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 48
- Registration Number
- NCT06054425
- Locations
- 🇺🇸
Anaheim Clinical Trials LLC /ID# 260740, Anaheim, California, United States
🇺🇸Clinical Pharmacology of Miami /ID# 260800, Miami, Florida, United States
🇺🇸Acpru /Id# 260864, Grayslake, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.